pharma news today glp-1 obesity drugs health october 2025 Outlook for obesity in 2025: more Upcoming wave of hormone-based therapies

Tissue Barriers

Related animal studies have further affirmed that Liraglutide can effectively suppress liver cancer progression in mouse models of diabetes and nonalcoholic steatohepatitis (NASH) [44]

50 Moreover, SEMA has significant benefits in improving clinical symptoms and quality of life for patients as well

Manufacturing capacity is catching up to demand, progressively lifting the supply constraints that have prevented GLP-1 prescriptions from being filled at the rate physicians would like to write them

Toxic fat is the cause of many cardiometabolic conditions, and GLP-1 drugs can help people reclaim their health

Eli Lilly retatrutide press release WEGOVY PRICE DROPS TO $349 PER MONTH November 2025 Effective November 17, 2025, Novo Nordisk has significantly reduced the price of its popular weight-loss drug, Wegovy